Kerecis Express (50250)
Kerecis Limited · Decision date Oct 30, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision for Kerecis Express (50250), a wound dressing with animal-derived material, under 510(k) number K260058. The applicant is Kerecis Limited of Isafjordur, Iceland. The decision date is 10/30/2026 and the date received is 01/08/2026. The primary classification product code is KGN, with FRO listed as a subsequent product code, and the review panel is General & Plastic Surgery. A SESE decision is a 510(k) clearance, not a PMA approval.
The record describes a traditional 510(k) that was not reviewed by a third party, is not a combination product, and has no authorized predetermined change control plan. The specialty field is listed as unknown. The source does not include a summary statement, so the specific indications, materials, or performance data supporting the clearance are not established here and remain in the underlying FDA documents.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Unknown
- Decision date
- Oct 30, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K260058
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Kerecis Limited
- Product code
- KGN
- Decision code
- SESE
- Decision date
- Oct 30, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Wound Dressing With Animal-Derived Material(S).
- Applicant
- Kerecis Limited
- Product code
- KGN
- FDA device class
- U
FDA decision timeline
K260058 received
Application receipt date recorded by FDA.
K260058 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code KGN
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Berkeley Advanced Biomaterials | 510(k) clearance | Oct 22, 2026 | FDA | |
epi-ConneKt Wound MatrixK260530 | MLM Biologics, Inc. | 510(k) clearance | Oct 15, 2026 | FDA |
ColActive PlusK260652 | Covalon Technologies, Ltd. | 510(k) clearance | Sep 9, 2026 | FDA |
| Berkeley Advanced Biomaterials | 510(k) clearance | Aug 27, 2026 | FDA | |
Collagen Wound PowderK260596 | Ventris Medical | 510(k) clearance | Jul 2, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Kerecis Limited
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Isafjordur
Sources and methodology
- Original FDA record: K260058
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


